Analysts Offer Predictions for argenx SE’s FY2026 Earnings (NASDAQ:ARGX)

argenx SE (NASDAQ:ARGX) – Stock analysts at Leerink Partnrs boosted their FY2026 EPS estimates for shares of argenx in a research report issued to clients and investors on Saturday, June 22nd. Leerink Partnrs analyst T. Smith now expects that the company will post earnings of $6.30 per share for the year, up from their previous forecast of $5.86. The consensus estimate for argenx’s current full-year earnings is ($2.75) per share.

ARGX has been the subject of several other reports. Wells Fargo & Company boosted their price target on argenx from $478.00 to $542.00 and gave the stock an “overweight” rating in a research report on Monday. Wedbush reaffirmed an “outperform” rating and issued a $521.00 price target on shares of argenx in a report on Thursday, April 18th. William Blair reiterated a “market perform” rating on shares of argenx in a report on Monday, June 17th. JMP Securities reduced their target price on argenx from $471.00 to $468.00 and set a “market outperform” rating on the stock in a research report on Friday, May 10th. Finally, Scotiabank raised their price target on argenx from $402.00 to $408.00 and gave the stock a “sector perform” rating in a report on Tuesday, March 26th. Five research analysts have rated the stock with a hold rating, fifteen have given a buy rating and one has issued a strong buy rating to the company’s stock. According to data from MarketBeat.com, argenx has an average rating of “Moderate Buy” and an average target price of $523.42.

argenx Stock Performance

Shares of ARGX opened at $440.59 on Tuesday. The stock has a market capitalization of $26.18 billion, a PE ratio of -77.84 and a beta of 0.65. The company has a 50 day moving average price of $376.64 and a 200-day moving average price of $386.49. argenx has a fifty-two week low of $327.73 and a fifty-two week high of $550.76.

argenx (NASDAQ:ARGX) last issued its earnings results on Monday, May 13th. The company reported ($1.04) earnings per share for the quarter, missing the consensus estimate of ($0.71) by ($0.33). The firm had revenue of $412.51 million during the quarter, compared to analysts’ expectations of $404.03 million. argenx had a negative return on equity of 14.14% and a negative net margin of 22.58%. During the same quarter in the prior year, the company posted ($0.52) earnings per share.

Institutional Investors Weigh In On argenx

Hedge funds have recently added to or reduced their stakes in the business. Wellington Management Group LLP raised its stake in shares of argenx by 26.2% during the 4th quarter. Wellington Management Group LLP now owns 279,168 shares of the company’s stock valued at $106,204,000 after buying an additional 57,956 shares during the last quarter. Sectoral Asset Management Inc. grew its holdings in argenx by 717.2% during the fourth quarter. Sectoral Asset Management Inc. now owns 10,027 shares of the company’s stock worth $3,815,000 after acquiring an additional 8,800 shares during the period. Boxer Capital LLC raised its position in argenx by 88.2% during the fourth quarter. Boxer Capital LLC now owns 160,000 shares of the company’s stock valued at $60,869,000 after acquiring an additional 75,000 shares in the last quarter. The Manufacturers Life Insurance Company lifted its holdings in argenx by 9.1% in the fourth quarter. The Manufacturers Life Insurance Company now owns 47,583 shares of the company’s stock valued at $18,102,000 after acquiring an additional 3,967 shares during the period. Finally, Raymond James Financial Services Advisors Inc. boosted its position in argenx by 30.4% in the 4th quarter. Raymond James Financial Services Advisors Inc. now owns 14,470 shares of the company’s stock worth $5,505,000 after purchasing an additional 3,374 shares in the last quarter. 60.32% of the stock is owned by hedge funds and other institutional investors.

About argenx

argenx SE, a biotechnology company, engages in the developing of various therapies for the treatment of autoimmune diseases in the United States, Japan, Europe, Middle East, Africa, and China. Its lead product candidate is efgartigimod for the treatment of patients with myasthenia gravis, immune thrombocytopenia, pemphigus vulgaris, generalized myasthenia gravis, chronic inflammatory demyelinating polyneuropathy, thyroid eye disease, bullous pemphigoid, myositis, primary sjögren's syndrome, post-covid postural orthostatic tachycardia syndrome, membranous nephropathy, lupus nephropathy, anca-associated vasculitis, and antibody mediated rejection; ENHANZE SC; Empasiprubart for multifocal motor neuropath, delayed graft function, and dermatomyositis; and ARGX-119 for congenital myasthenic syndrome and amyotrophic lateral sclerosis.